晚期尿路上皮癌严重影响患者生存。长期以来,以顺铂为基础的化疗方案作为晚期转移性尿路上皮癌的一线标准治疗方案,患者中位生存期仅8~14个月[1-3]。随着免疫时代的到来,多个程序性死亡-受体1(programmed cell death protein 1,PD-1)/...
详细信息
晚期尿路上皮癌严重影响患者生存。长期以来,以顺铂为基础的化疗方案作为晚期转移性尿路上皮癌的一线标准治疗方案,患者中位生存期仅8~14个月[1-3]。随着免疫时代的到来,多个程序性死亡-受体1(programmed cell death protein 1,PD-1)/程序性死亡-配体1(programmed cell death ligand 1,PD-L1)抑制剂被美国食品药品监督管理局(Food and Drug Administration,FDA)和国家药品监督管理局(National Medical Products Administration,NMPA)批准用于治疗晚期尿路上皮癌[4-6]。另外,成纤维生长因子受体(fibroblast growth factor receptor,FGFR)抑制剂与抗体偶联(antibody-drug conjugate,ADC)药物的研究取得突破,并先后被批准用于临床[7-11]。
Objective To elucidate the clinical features and treatment of Hemangiopericytomas (HPCs) in the central nervous system. Methods Twenty-six HPC operations performed at Huashan Hospital from January 1993 to June 1999 ...
详细信息
Objective To elucidate the clinical features and treatment of Hemangiopericytomas (HPCs) in the central nervous system. Methods Twenty-six HPC operations performed at Huashan Hospital from January 1993 to June 1999 were analyzed retrospectively, and a review of relevant literatures was done. Results Among the 26 cases, total tumor removal was achieved in 24 cases, and subtotal removal in 2 cases. Postoperatively, neurological symptoms were improved or unchanged in 21 cases, worsened in 4 cases, and pneumonia caused death in 1 case. Eighteen patients received postoperative radiotherapy. Eighteen patients were followed up from 1 month to 58 months (average, 22 months). During the follow-up period, 2 patients presented one or more distant metastasis, and one patient died of recurrence. Conclusion Surgical management is the best choice for treatment of patients with HPCs. Postoperative radiotherapy can postpone the risk of tumor recurrence.
暂无评论